Panbela Therapeutics Inc (PBLA) Stock Price, Trades & News

Panbela Therapeutics Inc is a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company's pipeline assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X), which provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity.

Financial Strength

	Name	Current	Vs Industry		Vs History

Growth Rank

	Name	Current	Vs Industry		Vs History

Momentum Rank

	Name	Current	Vs Industry		Vs History
	5-Day RSI	47.03
	9-Day RSI	43.34
	14-Day RSI	44.76
	3-1 Month Momentum %	5400
	6-1 Month Momentum %	5400
	12-1 Month Momentum %	-95.26

Liquidity Ratio

	Name	Current	Vs Industry		Vs History

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History

Profitability Rank

	Name	Current	Vs Industry		Vs History

GF Value Rank

	Name	Current	Vs Industry		Vs History
	EV-to-Forward-EBIT	-0.17
	EV-to-Forward-EBITDA	-0.17

Financials (Next Earnings Date:2026-07-03 Est.)

Annual Quarterly TTM

PBLA's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Gurus Latest Trades with OTCPK:PBLA

No Available Data

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Panbela Therapeutics Inc Executives

Details

GF Value™

PBLA

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected issues with PBLA. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil $)
	EPS (TTM) ($)	-18.717
	Beta	88.7253
	3-Year Sharpe Ratio	0.78
	3-Year Sortino Ratio	21.37
	Volatility %	6057.85
	14-Day RSI	44.76
	14-Day ATR ($)	0.001433
	20-Day SMA ($)	0.008475
	12-1 Month Momentum %	-95.26
	52-Week Range ($)	0.0001 - 2.5
	Shares Outstanding (Mil)	4.85

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	0
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Panbela Therapeutics Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Panbela Therapeutics Inc Stock Events

Financials Calendars

Event	Date	Price ($)
Third quarter earnings conference call for 2026	2026-11-13	In 135 days
Third quarter earnings results for 2026	2026-11-13	In 135 days
Second quarter earnings conference call for 2026	2026-07-20	In 19 days
Second quarter earnings results for 2026	2026-07-20	In 19 days
First quarter earnings conference call for 2026	2026-07-03	In 2 days
First quarter earnings results for 2026	2026-07-03	In 2 days
Third quarter earnings conference call for 2024	2024-11-14 16:30	0.32 (+0.00%)
Third quarter earnings results for 2024	2024-11-14	0.32 (+0.00%)
Second quarter earnings conference call for 2024	2024-08-13 16:30	0.35 (-6.67%)
Second quarter earnings results for 2024	2024-08-13	0.35 (-6.67%)

Show

Entries

Panbela Therapeutics Inc Frequently Asked Questions

What is Panbela Therapeutics Inc(PBLA)'s stock price today?

The current price of PBLA is $0.01. The 52 week high of PBLA is $2.50 and 52 week low is $0.00.

When is next earnings date of Panbela Therapeutics Inc(PBLA)?

The next earnings date of Panbela Therapeutics Inc(PBLA) is 2026-07-03 Est..

Does Panbela Therapeutics Inc(PBLA) pay dividends? If so, how much?

Panbela Therapeutics Inc(PBLA) does not pay dividend.

Guru Commentaries on OTCPK:PBLA

No articles.

Press Release

	Subject	Date
	PANBELA THERAPEUTICS INVESTOR ALERT - Kuznicki Law PLLC Investigates Panbela Therapeutics, Inc. - PBLA	2022-05-04
	PANBELA THERAPEUTICS INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Panbela Therapeutics, Inc. - PBLA	2022-04-07
	SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates MTOR, TEN, DWIN, PBLA	2022-02-28
	PANBELA THERAPEUTICS INVESTOR ALERT By The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Panbela Therapeutics, Inc. - PBLA	2022-02-25
	SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates HMHC, TGNA, MTOR, PBLA	2022-02-22
	PBLA Stock Investigation: Halper Sadeh LLP Is Investigating Whether the Merger of Panbela Therapeutics, Inc. Is Fair to Shareholders	2022-02-22
	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Panbela Therapeutics Inc. - PBLA	2021-02-18

10/Page

Articles on Panbela Therapeutics Inc

No articles.

Headlines

No news.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.